FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997643003> ?p ?o ?g. }

• W1997643003 endingPage "15" @default.
• W1997643003 startingPage "15" @default.
• W1997643003 abstract "In the United States, mortality associated with hepatitis C is on the rise and it has been estimated that 3.2–4 million persons in the United States have chronic HCV infection. In 1998, CDC recommended a risk-based approach to screening, with routine HCV testing for persons with risk factors including injection drug use, having received clotting factor concentrates produced before 1987, being on chronic hemodialysis, having persistently abnormal alanine aminotransferase levels, being a recipient of donated blood from a person who tested positive for HCV, or having received a blood transfusion or organ transplant before July 1992; in 1999, CDC recommended HCV testing for persons with HIV. However, risk-based screening strategies can be limited either by clinician reluctance to ask about risk factors or by patient unawareness or reluctance to disclose risk behaviors. As a result, use of risk-based strategies alone has resulted in a large proportion of infected persons remaining undiagnosed; in the United States, various estimates indicate that 45–85% of persons with HCV are unaware of their infection status. To augment risk-based screening, in 2012 CDC published a recommendation for one-time testing without prior ascertainment of HCV risk for persons born during 1945–1965. This birth-cohort approach was designed to both target persons with the highest prevalence of HCV infection and remove any behavioral stigma from screening. It has been estimated that with implementation of the birth-cohort screening strategy, 121,000 deaths from HCV will be averted and that screening is cost effective. Recently the USPSTF issued a final recommendation regarding HCV testing, assigning a Grade B to two recommendations: screening for HCV infection in persons at high risk for infection and one-time HCV screening for adults born between 1945 and 1965. Approximately 79 million persons were born during 1945–1965 (the Baby Boom Generation), making birth-cohort based screening a daunting task. Patients should first be tested for HCV antibody and those who are reactive for HCV antibody should next be tested with an FDA-approved nucleic acid testing assay for detection of HCV RNA indicative of current HCV infection. Rapid tests for HCV antibody allow access to HCV testing in settings lacking laboratory-based diagnostic services. Rapid tests for HCV antibody detection include OraQuick, which is approved by the FDA, as well as Chembio, MedMira and mBio, which are under development. In this talk we will evaluate both the rationale and implementation of screening for HCV and how to integrate novel technologies into the careening paradigm. [Correction added on 17 September 2013 after print publication: The Oral Papers section has been updated to include an online-only abstract, O112.]" @default.
• W1997643003 created "2016-06-24" @default.
• W1997643003 creator A5046885231 @default.
• W1997643003 date "2013-09-01" @default.
• W1997643003 modified "2023-09-23" @default.
• W1997643003 title "O112: Screening: saliva and blood-based screening assays" @default.
• W1997643003 doi "https://doi.org/10.1111/jvh.12165_24" @default.
• W1997643003 hasPublicationYear "2013" @default.
• W1997643003 type Work @default.
• W1997643003 sameAs 1997643003 @default.
• W1997643003 citedByCount "2" @default.
• W1997643003 countsByYear W19976430032014 @default.
• W1997643003 countsByYear W19976430032015 @default.
• W1997643003 crossrefType "journal-article" @default.
• W1997643003 hasAuthorship W1997643003A5046885231 @default.
• W1997643003 hasBestOaLocation W19976430031 @default.
• W1997643003 hasConcept C126322002 @default.
• W1997643003 hasConcept C203014093 @default.
• W1997643003 hasConcept C2522874641 @default.
• W1997643003 hasConcept C2776408679 @default.
• W1997643003 hasConcept C2776455275 @default.
• W1997643003 hasConcept C2777357209 @default.
• W1997643003 hasConcept C50440223 @default.
• W1997643003 hasConcept C71924100 @default.
• W1997643003 hasConcept C72563966 @default.
• W1997643003 hasConceptScore W1997643003C126322002 @default.
• W1997643003 hasConceptScore W1997643003C203014093 @default.
• W1997643003 hasConceptScore W1997643003C2522874641 @default.
• W1997643003 hasConceptScore W1997643003C2776408679 @default.
• W1997643003 hasConceptScore W1997643003C2776455275 @default.
• W1997643003 hasConceptScore W1997643003C2777357209 @default.
• W1997643003 hasConceptScore W1997643003C50440223 @default.
• W1997643003 hasConceptScore W1997643003C71924100 @default.
• W1997643003 hasConceptScore W1997643003C72563966 @default.
• W1997643003 hasIssue "s3" @default.
• W1997643003 hasLocation W19976430031 @default.
• W1997643003 hasOpenAccess W1997643003 @default.
• W1997643003 hasPrimaryLocation W19976430031 @default.
• W1997643003 hasRelatedWork W148047623 @default.
• W1997643003 hasRelatedWork W1965388675 @default.
• W1997643003 hasRelatedWork W1999474121 @default.
• W1997643003 hasRelatedWork W2017468821 @default.
• W1997643003 hasRelatedWork W2152944181 @default.
• W1997643003 hasRelatedWork W2315018325 @default.
• W1997643003 hasRelatedWork W2407357807 @default.
• W1997643003 hasRelatedWork W2642646575 @default.
• W1997643003 hasRelatedWork W3016662362 @default.
• W1997643003 hasRelatedWork W2553139507 @default.
• W1997643003 hasVolume "20" @default.
• W1997643003 isParatext "false" @default.
• W1997643003 isRetracted "false" @default.
• W1997643003 magId "1997643003" @default.
• W1997643003 workType "article" @default.